GH Research to Participate in Neuro Perspectives Conference

GH Research ( (GHRS) ) has shared an update.

GH Research PLC announced its participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, scheduled for June 16-17, 2025. The company plans to engage in one-on-one investor meetings and a fireside chat, which will be available on demand, potentially enhancing its visibility and investor relations in the neuropsychiatric treatment sector.

The most recent analyst rating on (GHRS) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.

Spark’s Take on GHRS Stock

According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.

GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.

To see Spark’s full report on GHRS stock, click here.

More about GH Research

GH Research PLC operates in the biotechnology industry, focusing on the development of novel treatments for psychiatric and neurological disorders.

Average Trading Volume: 184,387

Technical Sentiment Signal: Buy

Current Market Cap: $855.4M

For a thorough assessment of GHRS stock, go to TipRanks’ Stock Analysis page.